Drug Type Antibody drug conjugate (ADC) |
Synonyms BR96-Doxorubicin, cBR96-Doxorubicin Immunoconjugate, BMS-182248 + [5] |
Target |
Action inhibitors |
Mechanism Lewis-Y antigen inhibitors(Lewis-Y antigen inhibitors), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Cancer | Phase 2 | United States | 15 Jan 2003 | |
| Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 15 Jan 2003 | |
| Breast cancer recurrent | Phase 2 | United States | 01 Oct 2000 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | United States | 01 Oct 2000 | |
| Colorectal Cancer | Phase 2 | United States | - | - |
| Colorectal Cancer | Phase 2 | - | - | |
| Colorectal Cancer | Phase 2 | - | - | |
| Non-Small Cell Lung Cancer | Phase 2 | - | - | |
| Prostatic Cancer | Phase 2 | - | - |
Phase 2 | Non-Small Cell Lung Cancer Third line | 62 | symtsscmyh(ideimpeszw) = syuuobzcsu erpliydkak (olqyamdfxu ) | - | 15 Jul 2004 | ||
symtsscmyh(ideimpeszw) = hhfydaddik erpliydkak (olqyamdfxu ) |






